Today, Beactica Therapeutics is setting the pace in the cancer drug development landscape, with a strong focus on leveraging synthetic lethality to develop novel therapeutics for genetically defined cancers. This position at the forefront of the field, is rooted in Beactica’s unique heritage spanning decades of research and industrial development.
Prof. Helena Danielson at Uppsala University initiates collaboration with Biacore AB that results in adapting biosensor technology for small molecule drug discovery
Beactica is founded in Uppsala by Dr Per Källblad and Prof. Helena Danielson to pioneer fragment-based drug discovery using SPR biosensor technology
Beactica delivers key insights of the molecular interactions between cancer drug Afatinib (Giotrif®) and its cellular targets to Boehringer Ingelheim
Beactica enables the generation of TAK-831, a highly selective and potent inhibitor of D-amino acid oxidase (DAAO), that Takeda progresses to phase II trials in schizophrenia
Beactica enables the generation of the world's first highly potent and selective allosteric USP7 inhibitor that later is outlicensed by Almac to Genentech
Beactica initiates pilot work on an internal drug pipeline and closes its first financing round
Beactica and Janssen publish in PNAS on the identification of novel allosteric modulators for the alpha7 nicotinic acetylcholine receptor, further validating Beactica's platform
Beactica and Dong-A ST enter into license and collaboration agreement to develop novel cancer therapies targeting a family of epigenetic enzymes
Beactica changes name to Beactica Therapeutics to highlight the company's strategic focus on developing an internal pipeline of candidate drugs
Beactica Therapeutics aims its focus on leveraging synthetic lethality to tackle genetically defined cancers, with a vision to become a clinical-stage precision oncology company
Beactica Therapeutics gains full ownership of prioritised YAP–TEAD assets and add programme to its pipeline
This exceptional track record – in combination with the team's dedication to scientific excellence – showcases Beactica ability to steadily advance its position in the pharmaceutical R&D value chain.
Today, our vision is to become a clinical-stage precision oncology company with a pipeline of breakthrough therapeutics against genetically defined cancers.
Read more about our pipeline here.
Sign up for the Beactica newsletter to receive our latest news and updates